Is Pharmacogenomics Paired with AI the Antidote to the Global Cardiovascular Crisis?
Cardiovascular disease remains the world’s leading cause of death, claiming close to 20 million lives each year, with cases continuing to rise across…
-
-
Pharmacogenomics Is Transforming Drug Development and Patient Care: Insights from a Recent Study
Pharmacogenomics—the study of how an individual’s genetic makeup influences their response to medications—has become one of the most important pillars of modern personalized…
-
Machine Learning for pharmacogenomic variant effect predictions: Insights From a Recent Review
In the last decade, pharmacogenomics (PGx) has moved from a niche research domain into a central pillar of precision medicine. Sequencing is now…
-
OneOme to Shutdown, Deal a Blow to PGx Industry Momentum
OneOme, a leading name in pharmacogenomics testing and personalized medicine, has announced that it will cease operations by November 14, 2025, citing ongoing…
-
FDA’s Final Rule on Laboratory-Developed Tests: Implications for Pharmacogenomics
In May 2024, the U.S. Food and Drug Administration (FDA) published a final rule that would bring laboratory-developed tests (LDTs) explicitly under the…
-
APGxA Interview Series: Dr. Gualberto Ruaño, M.D., Ph.D. — Physician Scientist, Innovator, and Entrepreneur
When you talk to Dr. Gualberto Ruaño, you don’t just hear about science — you hear about purpose. A physician, geneticist, and entrepreneur,…
-
How to Navigate FDA Warnings About Unapproved Pharmacogenomic Claims
Pharmacogenetic testing has emerged as one of the most exciting frontiers in personalized medicine. By analyzing a patient’s genetic makeup, these tests promise…
-
Pharmacogenomic Data Submission: Guidelines for Clinicians and Industry Professionals
This blog provides a comprehensive overview of the FDA’s current and draft guidance on pharmacogenomic data submission, highlighting key regulatory requirements, submission algorithms, voluntary submissions, and practical considerations for clinicians and industry professionals.
-
Overcoming Barriers to Implementing PGx Testing in Routine Care
Learn about the barriers to Implementing PGx Testing
-
APGxA Company Spotlight: UGenome AI
UGenome AI is a US based biotech software company developing next-generation tools for genomic data interpretation. Co-founded by CEO Zachary S. Brooks, Chief Strategy Office Peter Bannister, and Chief Genomics Officer Dr. Jayden Lee, PharmD, EMBA, the company specializes in secondary and tertiary genomic analysis—transforming raw sequencing data into actionable, repeatable insights.
End of content
End of content